Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine in children with allergic rhinoconjunctivitis
2024-519550-36-00Phase 4Completed
- Sponsor
- Faes Farma S.A., A. Menarini Industrie Farmaceutiche Riunite S.r.l.
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of bilastine in allergic rhinoconjunctivitis (ARC), sponsored by Faes Farma S.A., A. Menarini Industrie Farmaceutiche Riunite S.r.l. Primary endpoint: Mean change in T5CSS score from baseline to day 14. Started Mar 2026; status: completed.
02
Drugs
bilastine
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2024-519550-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519550-36-00.